Skip to main content
Top
Published in: Virology Journal 1/2018

Open Access 01-12-2018 | Research

Genotype-specific and cross-reactive neutralizing antibodies induced by dengue virus infection: detection of antibodies with different levels of neutralizing activities against homologous and heterologous genotypes of dengue virus type 2 in common marmosets (Callithrix jacchus)

Authors: Nor Azila Muhammad Azami, Meng Ling Moi, Yasushi Ami, Yuriko Suzaki, Chang-Kweng Lim, Satoshi Taniguchi, Masayuki Saijo, Tomohiko Takasaki, Ichiro Kurane

Published in: Virology Journal | Issue 1/2018

Login to get access

Abstract

Background

A vaccine against all four dengue virus (DENV) serotypes includes the formulation of one genotype of each serotype. Although genetic similarities among genotypes within a serotype are higher as compared to those among serotypes, differences in the immunogenicity of the included genotypes would be a critical issue in maximizing successful dengue vaccine development. Thus, we determined the neutralizing antibody responses against three genotypes of dengue virus serotype 2 (DENV-2), namely Cosmopolitan, Asian I, and Asian/American, after primary and secondary inoculation with DENV-2 in a dengue animal model, the common marmoset (Callithrix jacchus).

Methods

A total of fifty-four plasma samples were obtained from thirty-four marmosets that were inoculated with clinically-isolated DENV strains or DENV candidate vaccines, were used in this study. Plasma samples were obtained from marmosets after primary inoculation with DENV-2 infection, secondary inoculation with homologous or heterologous genotypes, and tertiary inoculation with heterologous DENV. Neutralizing antibody titers against DENV-2 (Cosmopolitan, Asian I, and Asian/American genotypes) and DENV-1 were determined using a conventional plaque reduction neutralization assay.

Results

In marmosets that were inoculated with the Cosmopolitan genotype in primary infection, neutralizing antibody neutralized 3 genotypes, and the titers to Asian I genotype were significantly higher than those to homologous Cosmopolitan genotype. After secondary DENV-2 infection with heterologous genotype (Asian I in primary and Asian/American in secondary), neutralizing antibody titers to Asian/American genotype was significantly higher than those against Cosmopolitan and Asian I genotypes. Following tertiary infection with DENV-1 following DENV-2 Asian I and Cosmopolitan genotypes, neutralizing antibody titers to Asian/American were also significantly higher than those against Cosmopolitan and Asian I genotypes.

Conclusion

The present study demonstrated that different levels of neutralizing antibodies were induced against variable DENV-2 genotypes after primary, secondary and tertiary infections, and that neutralizing antibody titers to some heterologous genotypes were higher than those to homologous genotypes within a serotype. The results indicate that heterogeneity and homogeneity of infecting genotypes influence the levels and cross-reactivity of neutralizing antibodies induced in following infections. The results also suggest that certain genotypes may possess advantage in terms of breakthrough infections against vaccination.
Appendix
Available only for authorised users
Literature
3.
go back to reference WHO. Dengue guidelines for diagnosis, treatment, prevention and control: new edition. Geneva: World Health organization; 2009. WHO. Dengue guidelines for diagnosis, treatment, prevention and control: new edition. Geneva: World Health organization; 2009.
5.
go back to reference Usme-Ciro JA, Méndez JA, Laiton KD, Páez A. The relevance of dengue virus genotypes surveillance at country level before vaccine approval. Hum Vaccin Immunother. 2014;10:2674–8. Taylor & Francis. Available from: http://dx.doi.org/10.4161/hv.29563.CrossRefPubMedPubMedCentral Usme-Ciro JA, Méndez JA, Laiton KD, Páez A. The relevance of dengue virus genotypes surveillance at country level before vaccine approval. Hum Vaccin Immunother. 2014;10:2674–8. Taylor & Francis. Available from: http://​dx.​doi.​org/​10.​4161/​hv.​29563.​CrossRefPubMedPubMedCentral
6.
go back to reference Brien JD, Austin SK, Sukupolvi-Petty S, O’Brien KM, Johnson S, Fremont DH, et al. Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol. 2010;84:10630–43.CrossRefPubMedPubMedCentral Brien JD, Austin SK, Sukupolvi-Petty S, O’Brien KM, Johnson S, Fremont DH, et al. Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol. 2010;84:10630–43.CrossRefPubMedPubMedCentral
10.
go back to reference Moi ML, Lim CK, Kotaki A, Takasaki T, Kurane I. Discrepancy in dengue virus neutralizing antibody titers between plaque reduction neutralizing tests with fc gamma receptor (fc gamma R)-negative and fc gamma R-expressing BHK-21 cells. Clin Vaccine Immunol. 2010;17:402–7.CrossRefPubMed Moi ML, Lim CK, Kotaki A, Takasaki T, Kurane I. Discrepancy in dengue virus neutralizing antibody titers between plaque reduction neutralizing tests with fc gamma receptor (fc gamma R)-negative and fc gamma R-expressing BHK-21 cells. Clin Vaccine Immunol. 2010;17:402–7.CrossRefPubMed
15.
go back to reference Moi MLL, Takasaki T, Omatsu T, Nakamura S, Katakai Y, Ami Y, et al. Demonstration of marmosets (Callithrix jacchus) as a non-human primate model for secondary dengue virus infection: high levels of viraemia and serotype cross-reactive antibody responses consistent with secondary infection of humans. J Gen Virol. 2014;95:591–600.CrossRefPubMed Moi MLL, Takasaki T, Omatsu T, Nakamura S, Katakai Y, Ami Y, et al. Demonstration of marmosets (Callithrix jacchus) as a non-human primate model for secondary dengue virus infection: high levels of viraemia and serotype cross-reactive antibody responses consistent with secondary infection of humans. J Gen Virol. 2014;95:591–600.CrossRefPubMed
20.
go back to reference Lai C-Y, Tsai W-Y, Lin S-R, Kao C-L, Hu H-P, King C-C, et al. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol. 2008;82:6631–43. American Society for Microbiology. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18448542. Cited 28 May 2017.CrossRefPubMedPubMedCentral Lai C-Y, Tsai W-Y, Lin S-R, Kao C-L, Hu H-P, King C-C, et al. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol. 2008;82:6631–43. American Society for Microbiology. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​18448542. Cited 28 May 2017.CrossRefPubMedPubMedCentral
22.
Metadata
Title
Genotype-specific and cross-reactive neutralizing antibodies induced by dengue virus infection: detection of antibodies with different levels of neutralizing activities against homologous and heterologous genotypes of dengue virus type 2 in common marmosets (Callithrix jacchus)
Authors
Nor Azila Muhammad Azami
Meng Ling Moi
Yasushi Ami
Yuriko Suzaki
Chang-Kweng Lim
Satoshi Taniguchi
Masayuki Saijo
Tomohiko Takasaki
Ichiro Kurane
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2018
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-018-0967-x

Other articles of this Issue 1/2018

Virology Journal 1/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.